Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05285839
PHASE4
Dupixent and Narrowband UVB for Atopic Dermatitis
Sponsor: Psoriasis Treatment Center of Central New Jersey
View on ClinicalTrials.gov
Summary
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Official title: Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination With Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2022-04-19
Completion Date
2024-12-15
Last Updated
2024-03-15
Healthy Volunteers
No
Conditions
Interventions
DRUG
Dupixent
dupilumab 300mg
Locations (1)
Eczema Treatment Center of New Jersey
East Windsor, New Jersey, United States